EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral Glucose Tolerance Test (OGTT) Evidence for the Postprandial Anti-Hyperglycemic Property of Salacca zalacca (Gaertn.) Voss Seed Extract

Vilasinee Hirunpanich Sato iD, Savita Chewchinda iD, Arman Syah Goli iD, Hitoshi Sato iD, Jannarin Nontakham iD, Boonyadist Vongsak iD

Molecules · 23.09.2023 · 28 (19) · 6775

DOI: 10.3390/molecules28196775 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 23.09.2023. Verfasst von Vilasinee Hirunpanich Sato und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Burapha University, Pharmaceutical Innovations of Natural Products Unit (PhInNat).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Salak seed extract (Salacca zalacca) is known for its high antioxidant content and low caffeine levels, making it a promising candidate for the development of value-added health products. However, there is a lack of scientific evidence for its anti-hyperglycemic effects. To address this, we investigated the in vitro and in vivo anti-hyperglycemic and antioxidant effects of salak seed extract. The HPLC chromatogram of salak seed extract shows a prominent peak that corresponds to chlorogenic acid. In vitro studies revealed that salak seeds inhibited α-glucosidase activity and glucose uptake in Caco-2 cells in a concentration-dependent manner, while also exhibiting antioxidant properties. The extract exhibits a non-competitive inhibition on α-glucosidase activity, with an IC50 and Ki of 16.28 ± 7.22 and 24.81 μg/mL, respectively. In vivo studies utilizing streptozotocin-nicotinamide-induced diabetic mice showed that the extract significantly reduced fasting blood glucose (FBG) levels in the oral glucose tolerance test. Continuous administration of the salak seed extract resulted in lower FBG levels by 13.8% as compared with untreated diabetic mice, although this change was not statistically significant. The estimated LD50 value of salak seed extract exceeds 2000 mg/kg, and no toxicity symptoms have been detected. Our research supports that salak seed extract has the potential to serve as a functional food or supplement that may be beneficial in reducing postprandial hyperglycemia among people with type 2 diabetes. This effect was explained by the salak’s inhibitory mechanisms of glucose absorption due to inhibition of both α-glucosidase activity and intestinal glucose uptake, coupled with its antioxidant effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetes Mellitus, ExperimentalMiceHumansAnimalsGlucose Tolerance Testalpha-GlucosidasesAntioxidantsPlant ExtractsCaco-2 CellsGlucoseSeedsHypoglycemic AgentsBlood Glucose

Stichwörter der Autor:innen

Salaccaalpha-glucosidasediabetesglucose uptakeoral glucose tolerance testpostprandial hyperglycemiasalak seed extract

Substanzen

alpha-GlucosidasesAntioxidantsPlant ExtractsGlucoseHypoglycemic AgentsBlood Glucose

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand.
  • Department of Food Chemistry, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand.
  • Division of Pharmacokinetics and Pharmacodynamics, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa University, Tokyo 142-855, Japan.
  • Clinical Research Section, Division of Research and Academic Support, National Cancer Institute, Bangkok 10400, Thailand.
  • Pharmaceutical Innovations of Natural Products Unit (PhInNat), Burapha University, Chonburi 20131, Thailand.
  • Faculty of Pharmaceutical Sciences, Burapha University, Chonburi 20131, Thailand.

ORCID-Profile: Vilasinee Hirunpanich Sato, Savita Chewchinda, Arman Syah Goli, Hitoshi Sato, Jannarin Nontakham, Boonyadist Vongsak

Förderung

  • Burapha University
  • Pharmaceutical Innovations of Natural Products Unit (PhInNat)

Zitieren

APA

Sato, V. H., Chewchinda, S., Goli, A. S., Sato, H., Nontakham, J., & Vongsak, B. (2023). Oral Glucose Tolerance Test (OGTT) Evidence for the Postprandial Anti-Hyperglycemic Property of Salacca zalacca (Gaertn.) Voss Seed Extract. Molecules, 28(19), 6775. https://doi.org/10.3390/molecules28196775

Vancouver

Sato VH, Chewchinda S, Goli AS, Sato H, Nontakham J, Vongsak B. Oral Glucose Tolerance Test (OGTT) Evidence for the Postprandial Anti-Hyperglycemic Property of Salacca zalacca (Gaertn.) Voss Seed Extract. Molecules. 2023;28(19):6775. doi:10.3390/molecules28196775

BibTeX
@article{Sato2023,
  author = {Sato, Vilasinee Hirunpanich and Chewchinda, Savita and Goli, Arman Syah and Sato, Hitoshi and Nontakham, Jannarin and Vongsak, Boonyadist},
  title = {Oral Glucose Tolerance Test (OGTT) Evidence for the Postprandial Anti-Hyperglycemic Property of Salacca zalacca (Gaertn.) Voss Seed Extract},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {19},
  pages = {6775},
  doi = {10.3390/molecules28196775}
}
Kostenlos starten →